American Association for Cancer Research– tag –
-
Antibody-Drug Conjugates Prepared with Peptide Asparaginyl Ligase Enhance Uniformity and Antitumor Activity, Promising Pharmaceutical Applications
Molecular Cancer Therapeutics (AACR Journals) USA Overview Novel antibody-drug conjugates (ADCs) prepared using peptide asparaginyl ligase (PAL) demonstrated potent antitumor activity in both in vitro and in vivo models. This innovative ... -
FDA Grants Breakthrough Therapy and Fast Track Designations to Norroy Bioscience’s 68Ga-NYM096 for Clear Cell Renal Cell Carcinoma PET Imaging, First Chinese-Origin Radiopharmaceutical to Receive BTD
Targeted Oncology USA Overview The U.S. FDA has granted Breakthrough Therapy Designation (BTD) and Fast Track Designation (FTD) to Norroy Bioscience's investigational PET imaging agent, 68Ga-NYM096, for detecting clear cell renal cell ca... -
Next-Gen ADCs Show Transformative Efficacy: 46% ORR in Platinum-Resistant Gynecological Cancers, up to 50% ORR in Nasopharyngeal Cancer at AACR 2026
AACR Annual Meeting 2026 USA Overview The AACR Annual Meeting 2026 highlighted groundbreaking clinical results for next-generation Antibody-Drug Conjugates (ADCs), demonstrating significant advances in targeted cancer therapy. A combinat... -
FDA Approves Dato-DXd (Datroway) for Metastatic Triple-Negative Breast Cancer based on Phase III TROPION-Breast02 Trial
Cancer Network USA Overview The U.S. FDA has approved datopotamab deruxtecan-dlnk (Dato-DXd; Datroway) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are ineligible for PD-1/PD-L1 immune check... -
FDA Approves First-in-Class PROTAC Degrader Vepdegestrant for ESR1-Mutated Breast Cancer, Improving Progression-Free Survival by 43%
Dana-Farber Cancer Institute USA Overview The U.S. FDA has approved vepdegestrant (Veppanu), a first-in-class PROTAC (Proteolysis-Targeting Chimera) degrader, for patients with ER-positive, HER2-negative metastatic breast cancer harborin... -
Tango Therapeutics Unveils TNG961, First Selective Oral HBS1L Molecular Glue Degrader for FOCAD-Deleted Cancers, a New Precision Oncology Strategy
AACR Journals (Cancer Discovery) USA Overview Tango Therapeutics announced the development of TNG961, the first selective oral HBS1L molecular glue degrader targeting FOCAD-deleted cancers. TNG961 induces translational arrest by disrupti... -
DelveInsight Reports Over 80 Molecular Glue Drug Candidates in Clinical Pipeline, Highlighting Market Boom
GlobeNewswire USA Overview DelveInsight's comprehensive report reveals over 80 molecular glue drug candidates in clinical development, signifying rapid expansion in this novel therapeutic modality. Key advancements include Nested Therape... -
Arvinas/Pfizer’s PROTAC Drug Veppanu Receives Historic FDA Approval for ESR1-Mutant Advanced Breast Cancer, Demonstrating 43% PFS Risk Reduction
Cancer Discovery - AACR Journals USA Overview Arvinas and Pfizer's oral PROTAC drug, Veppanu, has received FDA approval for advanced breast cancer with ESR1 mutations, marking the first clinical validation of targeted protein degradation... -
NEOK002: Next-Generation Bispecific ADC Targeting EGFR and MUC1 Enters Clinical Development for Solid Tumors
Conference Coverage AACR USA Overview NEOK002 (formerly ABL209), a bispecific antibody-drug conjugate (ADC), has entered clinical development, designed to concurrently target two key cancer antigens, EGFR and MUC1, implicated in epitheli...
1